Human Immunodeficiency Virus Type 1 Treatment Market Expands with Breakthrough HIV Vaccines and Gene Therapy Trials

"Global Human Immunodeficiency Virus Type-1 (HIV-1) Treatment Market reached US$39,670.14 million in 2023 and is expected to reach US$62,752.56 million by 2031, growing at a CAGR of 5.9% during the forecast period 2024-2031," according to DataM Intelligence.

The HIV 1 treatment market is dominated by established pharmaceutical leaders such as Gilead Sciences, ViiV Healthcare, Janssen, Viatris, and Merck, which offer a wide range of antiretroviral therapies (ARTs), including fixed-dose combinations and long-acting injectables. GSK plc., Bristol Myers Squibb, Boehringer Ingelheim, AbbVie, and Celltrion Inc. play vital roles through innovation in novel ART compounds, biosimilars, and PrEP products.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/human-immunodeficiency-virus-type-1-treatment-market?jd

Human Immunodeficiency Virus Type 1 Treatment Market M&A & Strategic Collaborations

1. ViiV Healthcare acquires long-acting ART platform from Aruvant Sciences (June 2025), gaining access to novel Penta binding scaffold therapy under co-development terms.
2. Gilead Sciences licenses CAR T HIV reservoir targeting tech from Excision BioTherapeutics (May 2025), enhancing its pipeline for potential ART-free remission solutions.
3. Janssen-Celltrion partnership (July 2025) jointly develops biosimilars of key ART regimens to expand access in emerging markets across Africa and Asia.

These strategic moves illustrate the market's focus on long-acting therapy platforms, gene editing technology licensing, and biosimilar deployment agreements rather than traditional M&A acquisitions.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/human-immunodeficiency-virus-type-1-treatment-market?jd

Key Growth Drivers & Emerging Opportunities in the HIV 1 Treatment Market

• Shift toward long-acting injectables and extended release formulations for improved adherence.
• Increased global ARV access in low and middle-income countries through generic uptake and pricing partnerships.
• Innovations in cure research, including CAR T, gene editing, and therapeutic vaccines.
• Expanding use of telehealth and decentralized care models to support treatment continuity and patient engagement.
• Growing focus on prevention, including PrEP, microbicides, and integrase-based multipurpose therapies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=human-immunodeficiency-virus-type-1-treatment-market?jd

Regional Market Drivers in the HIV 1 Treatment Market

North America leads with high ART penetration, insurance support, and ongoing PrEP adoption.
Europe benefits from robust public health systems, ART reimbursement, and early access schemes for innovative therapies.
Asia Pacific exhibits rapid growth driven by expanding ART programs, rising HIV awareness, and generic ARV production.
Latin America focuses on community-based HIV care and multi-stakeholder health campaigns, boosting treatment linkages.
The Middle East & Africa are emerging markets with expanding donor-funded ART initiatives and regional generics manufacturing.

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.